Subcutaneous abdominal adipose tissue subcompartments

Potential role in rosiglitazone effects

Gillian E. Walker, Paolo Marzullo, Barbara Verti, Gabriele Guzzaloni, Sabrina Maestrini, Francesco Zurleni, Antonio Liuzzi, Anna Maria Di Blasio

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Abdominal visceral tissue (VAT) and subcutaneous adipose tissue (SAT), comprised of superficial-SAT (sSAT) and deep-SAT (dSAT), are metabolically distinct. The antidiabetic agents thiazolidinediones (TZDs), in addition to their insulin-sensitizing effects, redistribute SAT suggesting that TZD action involves adipose tissue depot-specific regulation. We investigated the expression of proteins key to adipocyte metabolism on differentiated first passage (P1) preadipocytes treated with rosiglitazone, to establish a role for the diverse depots of abdominal adipose tissue in the insulin-sensitizing effects of TZDs. Adipocytes and preadipocytes were isolated from sSAT, dSAT, and VAT samples obtained from eight normal subjects. Preadipocytes (P1) left untreated (U) or treated with a classic differentiation cocktail (DI) including rosiglitazone (DIR) for 9 days were evaluated for strata-specific differences in differentiation including peroxisome proliferator-activated receptor-γ (PPAR-γ) and lipoprotein lipase (LPL) expression, insulin sensitivity via adiponectin and glucose transport-4 (GLUT4), glucocorticoid metabolism with 11Β-hydroxysteroid dehydrogenase type-1 (11ΒHSD1), and alterations in the adipokine leptin. While depot-specific differences were absent with the classic differentiation cocktail, with rosiglitazone sSAT had the most potent response followed by dSAT, whereas VAT was resistant to differentiation. With rosiglitazone, universal strata effects were observed for PPAR-γ, LPL, and leptin, with VAT in all cases expressing significantly lower basal expression levels. Clear dSAT-specific changes were observed with decreased intracellular GLUT4. Specific sSAT alterations included decreased 11ΒHSD1 whereas secreted adiponectin was potently upregulated in sSAT with respect to dSAT and VAT. Overall, the subcompartments of SAT, sSAT, and dSAT, appear to participate in the metabolic changes that arise with rosiglitazone administration.

Original languageEnglish
Pages (from-to)1983-1991
Number of pages9
JournalObesity
Volume16
Issue number9
DOIs
Publication statusPublished - Sep 2008

Fingerprint

rosiglitazone
Abdominal Subcutaneous Fat
Subcutaneous Fat
Thiazolidinediones
11-beta-Hydroxysteroid Dehydrogenases
Peroxisome Proliferator-Activated Receptors
Lipoprotein Lipase
Adiponectin
Leptin
Adipocytes
Insulin
Glucose
Abdominal Fat
Adipokines
Hypoglycemic Agents
Glucocorticoids
Insulin Resistance
Adipose Tissue

ASJC Scopus subject areas

  • Endocrinology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Subcutaneous abdominal adipose tissue subcompartments : Potential role in rosiglitazone effects. / Walker, Gillian E.; Marzullo, Paolo; Verti, Barbara; Guzzaloni, Gabriele; Maestrini, Sabrina; Zurleni, Francesco; Liuzzi, Antonio; Di Blasio, Anna Maria.

In: Obesity, Vol. 16, No. 9, 09.2008, p. 1983-1991.

Research output: Contribution to journalArticle

@article{54735ea62c8a4eddad238dd3806b840b,
title = "Subcutaneous abdominal adipose tissue subcompartments: Potential role in rosiglitazone effects",
abstract = "Abdominal visceral tissue (VAT) and subcutaneous adipose tissue (SAT), comprised of superficial-SAT (sSAT) and deep-SAT (dSAT), are metabolically distinct. The antidiabetic agents thiazolidinediones (TZDs), in addition to their insulin-sensitizing effects, redistribute SAT suggesting that TZD action involves adipose tissue depot-specific regulation. We investigated the expression of proteins key to adipocyte metabolism on differentiated first passage (P1) preadipocytes treated with rosiglitazone, to establish a role for the diverse depots of abdominal adipose tissue in the insulin-sensitizing effects of TZDs. Adipocytes and preadipocytes were isolated from sSAT, dSAT, and VAT samples obtained from eight normal subjects. Preadipocytes (P1) left untreated (U) or treated with a classic differentiation cocktail (DI) including rosiglitazone (DIR) for 9 days were evaluated for strata-specific differences in differentiation including peroxisome proliferator-activated receptor-γ (PPAR-γ) and lipoprotein lipase (LPL) expression, insulin sensitivity via adiponectin and glucose transport-4 (GLUT4), glucocorticoid metabolism with 11Β-hydroxysteroid dehydrogenase type-1 (11ΒHSD1), and alterations in the adipokine leptin. While depot-specific differences were absent with the classic differentiation cocktail, with rosiglitazone sSAT had the most potent response followed by dSAT, whereas VAT was resistant to differentiation. With rosiglitazone, universal strata effects were observed for PPAR-γ, LPL, and leptin, with VAT in all cases expressing significantly lower basal expression levels. Clear dSAT-specific changes were observed with decreased intracellular GLUT4. Specific sSAT alterations included decreased 11ΒHSD1 whereas secreted adiponectin was potently upregulated in sSAT with respect to dSAT and VAT. Overall, the subcompartments of SAT, sSAT, and dSAT, appear to participate in the metabolic changes that arise with rosiglitazone administration.",
author = "Walker, {Gillian E.} and Paolo Marzullo and Barbara Verti and Gabriele Guzzaloni and Sabrina Maestrini and Francesco Zurleni and Antonio Liuzzi and {Di Blasio}, {Anna Maria}",
year = "2008",
month = "9",
doi = "10.1038/oby.2008.326",
language = "English",
volume = "16",
pages = "1983--1991",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Subcutaneous abdominal adipose tissue subcompartments

T2 - Potential role in rosiglitazone effects

AU - Walker, Gillian E.

AU - Marzullo, Paolo

AU - Verti, Barbara

AU - Guzzaloni, Gabriele

AU - Maestrini, Sabrina

AU - Zurleni, Francesco

AU - Liuzzi, Antonio

AU - Di Blasio, Anna Maria

PY - 2008/9

Y1 - 2008/9

N2 - Abdominal visceral tissue (VAT) and subcutaneous adipose tissue (SAT), comprised of superficial-SAT (sSAT) and deep-SAT (dSAT), are metabolically distinct. The antidiabetic agents thiazolidinediones (TZDs), in addition to their insulin-sensitizing effects, redistribute SAT suggesting that TZD action involves adipose tissue depot-specific regulation. We investigated the expression of proteins key to adipocyte metabolism on differentiated first passage (P1) preadipocytes treated with rosiglitazone, to establish a role for the diverse depots of abdominal adipose tissue in the insulin-sensitizing effects of TZDs. Adipocytes and preadipocytes were isolated from sSAT, dSAT, and VAT samples obtained from eight normal subjects. Preadipocytes (P1) left untreated (U) or treated with a classic differentiation cocktail (DI) including rosiglitazone (DIR) for 9 days were evaluated for strata-specific differences in differentiation including peroxisome proliferator-activated receptor-γ (PPAR-γ) and lipoprotein lipase (LPL) expression, insulin sensitivity via adiponectin and glucose transport-4 (GLUT4), glucocorticoid metabolism with 11Β-hydroxysteroid dehydrogenase type-1 (11ΒHSD1), and alterations in the adipokine leptin. While depot-specific differences were absent with the classic differentiation cocktail, with rosiglitazone sSAT had the most potent response followed by dSAT, whereas VAT was resistant to differentiation. With rosiglitazone, universal strata effects were observed for PPAR-γ, LPL, and leptin, with VAT in all cases expressing significantly lower basal expression levels. Clear dSAT-specific changes were observed with decreased intracellular GLUT4. Specific sSAT alterations included decreased 11ΒHSD1 whereas secreted adiponectin was potently upregulated in sSAT with respect to dSAT and VAT. Overall, the subcompartments of SAT, sSAT, and dSAT, appear to participate in the metabolic changes that arise with rosiglitazone administration.

AB - Abdominal visceral tissue (VAT) and subcutaneous adipose tissue (SAT), comprised of superficial-SAT (sSAT) and deep-SAT (dSAT), are metabolically distinct. The antidiabetic agents thiazolidinediones (TZDs), in addition to their insulin-sensitizing effects, redistribute SAT suggesting that TZD action involves adipose tissue depot-specific regulation. We investigated the expression of proteins key to adipocyte metabolism on differentiated first passage (P1) preadipocytes treated with rosiglitazone, to establish a role for the diverse depots of abdominal adipose tissue in the insulin-sensitizing effects of TZDs. Adipocytes and preadipocytes were isolated from sSAT, dSAT, and VAT samples obtained from eight normal subjects. Preadipocytes (P1) left untreated (U) or treated with a classic differentiation cocktail (DI) including rosiglitazone (DIR) for 9 days were evaluated for strata-specific differences in differentiation including peroxisome proliferator-activated receptor-γ (PPAR-γ) and lipoprotein lipase (LPL) expression, insulin sensitivity via adiponectin and glucose transport-4 (GLUT4), glucocorticoid metabolism with 11Β-hydroxysteroid dehydrogenase type-1 (11ΒHSD1), and alterations in the adipokine leptin. While depot-specific differences were absent with the classic differentiation cocktail, with rosiglitazone sSAT had the most potent response followed by dSAT, whereas VAT was resistant to differentiation. With rosiglitazone, universal strata effects were observed for PPAR-γ, LPL, and leptin, with VAT in all cases expressing significantly lower basal expression levels. Clear dSAT-specific changes were observed with decreased intracellular GLUT4. Specific sSAT alterations included decreased 11ΒHSD1 whereas secreted adiponectin was potently upregulated in sSAT with respect to dSAT and VAT. Overall, the subcompartments of SAT, sSAT, and dSAT, appear to participate in the metabolic changes that arise with rosiglitazone administration.

UR - http://www.scopus.com/inward/record.url?scp=50649102114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649102114&partnerID=8YFLogxK

U2 - 10.1038/oby.2008.326

DO - 10.1038/oby.2008.326

M3 - Article

VL - 16

SP - 1983

EP - 1991

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 9

ER -